Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) traded up 8.3% during mid-day trading on Tuesday . The company traded as high as $15.27 and last traded at $15.27. 45,693 shares traded hands during trading, a decline of 74% from the average session volume of 176,201 shares. The stock had previously closed at $14.10.
Analyst Ratings Changes
SION has been the topic of several analyst reports. Wall Street Zen cut Sionna Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Guggenheim started coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating and a $45.00 price objective for the company. Stifel Nicolaus started coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating and a $32.00 price objective for the company. Finally, TD Cowen assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They issued a "buy" rating on the stock.
Check Out Our Latest Analysis on SION
Sionna Therapeutics Trading Up 13.8%
The company's 50-day moving average price is $13.54.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.17).
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in SION. TD Asset Management Inc acquired a new position in Sionna Therapeutics in the 1st quarter worth approximately $579,000. Goldman Sachs Group Inc. purchased a new position in shares of Sionna Therapeutics during the first quarter valued at $667,000. Charles Schwab Investment Management Inc. purchased a new stake in Sionna Therapeutics in the 1st quarter worth about $676,000. Woodline Partners LP purchased a new stake in Sionna Therapeutics in the 1st quarter worth about $837,000. Finally, CenterBook Partners LP purchased a new position in Sionna Therapeutics during the 1st quarter valued at about $1,195,000.
Sionna Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
